NASDAQ$ANIP
ANI Pharmaceuticals Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
ANI Pharmaceuticals' rare disease business is expected to drive growth, with Purified Cortrophin® Gel as the lead asset, expanding through M&A and in-licensing.
ANI Pharmaceuticals is focusing on its rare disease business, particularly Purified Cortrophin® Gel, as a primary growth driver. The company is expanding its rare disease platform through strategic initiatives, including M&A and in-licensing, and is targeting key therapeutic areas such as nephrology, neurology, rheumatology, pulmonology, and ophthalmology to increase its market presence and revenue.
- Rare Disease business is expected to be the largest driver of growth.
- Q1 2024 Rare Disease Revenues were $37 million, a 126% year-over-year increase.
- Estimated 2024 Rare Disease Revenues are projected to be $170-$180 million, representing a 52%-61% year-over-year growth.
- Expanding the scope and scale of Rare Disease business through M&A and in-licensing remains a high priority.
Headline financials
Revenue & EPS history
ANI Pharmaceuticals · Revenue · Quarterly
$137M
Revenue by segment
ANI Pharmaceuticals · $57.6M total across 2 segments · Q1 2022
- Generic Products$49.1M+48.8%85.2%
- Brands$8.5M+13.3%14.8%
Forward guidance
ANI Pharmaceuticals anticipates growth in its rare disease business, especially with Purified Cortrophin® Gel. The company expects to expand its market presence through strategic initiatives like M&A and in-licensing, targeting key therapeutic areas. Revenue projections for 2024 are estimated between $520 million and $542 million.
Tailwinds
- Expansion into new therapeutic areas like ophthalmology and pulmonology is expected to meaningfully drive Cortrophin growth.
- Ongoing efforts to enhance support and remove challenges for patients starting on ACTH therapy.
- Plans to use strong balance sheet and well-proven platform to expand through M&A and in-licensing of commercial or near-commercial products.
- Continued prescription growth for original therapeutic areas of neurology, nephrology and rheumatology.
- Prescribing momentum across existing and new prescribers.
Headwinds
- Commercial success depends on expanding the market and gaining market share with Cortrophin Gel.
- Acquisitions and other investments could disrupt business and harm financial position and operating results.
- Dependence on single source suppliers of ingredients due to the time and cost to validate a second source of supply.
- Ability to develop, license or acquire, and commercialize new products.
- The impact of legislative or regulatory reform on the pricing for pharmaceutical products.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
-1.2%
Avg return
Earnings day
-3.0%
Avg return
5 days after
-2.8%
Avg return
30 days after
38%
24 / 64 earnings
Positive
+52.1%
Q3 2021
Best reaction
-24.6%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.4% | -3.7% | -3.4% | |
| Q4 2025 | -3.9% | -0.8% | -5.6% | |
| Q3 2025 | +0.4% | -3.3% | -9.4% | |
| Q1 2025 | -7.5% | -15.6% | -13.4% | |
| Q4 2024 | +13.4% | +6.3% | +10.7% | |
| Q3 2024 | +5.8% | +2.5% | -2.4% | |
| Q2 2024 | -3.6% | -2.1% | +2.7% | |
| Q1 2024 | +2.2% | -1.6% | +1.3% | |
| Q4 2023 | +11.4% | -0.2% | +3.0% | |
| Q3 2023 | -17.9% | -18.8% | -23.1% | |
| Q2 2023 | +8.4% | +9.2% | +10.7% | |
| Q1 2023 | +13.5% | +6.5% | +26.2% | |
| Q4 2022 | -5.3% | -6.0% | -11.5% | |
| Q3 2022 | -5.1% | -4.7% | +3.2% | |
| Q2 2022 | -1.8% | +8.2% | +7.3% | |
| Q1 2022 | -5.9% | +1.3% | +6.9% | |
| Q4 2021 | -24.6% | -23.6% | -9.8% | |
| Q3 2021 | +52.1% | +33.8% | +8.2% | |
| Q2 2021 | -7.9% | -8.5% | -11.5% | |
| Q1 2021 | -6.0% | -4.1% | -1.8% | |
| Q4 2020 | +4.1% | +6.6% | +5.3% | |
| Q3 2020 | -15.9% | -3.5% | +4.1% | |
| Q2 2020 | -2.0% | +0.7% | -6.0% | |
| Q1 2020 | -7.0% | -12.1% | -13.0% | |
| Q4 2019 | -19.1% | -8.1% | -41.2% | |
| Q3 2019 | -22.2% | -27.3% | -24.7% | |
| Q2 2019 | -10.8% | -13.7% | -21.0% | |
| Q1 2019 | +3.1% | -1.7% | -0.3% | |
| Q4 2018 | +7.7% | +0.1% | +8.6% | |
| Q3 2018 | +7.2% | +2.1% | -0.2% | |
| Q2 2018 | -13.0% | -13.1% | -13.7% | |
| Q1 2018 | +3.9% | +3.9% | +9.6% | |
| Q4 2017 | +11.3% | -3.8% | +0.6% | |
| Q3 2017 | +7.7% | +4.2% | +22.8% | |
| Q2 2017 | -2.9% | -3.8% | +6.3% | |
| Q1 2017 | -2.0% | +0.7% | -10.3% | |
| Q4 2016 | -16.3% | -18.0% | -17.2% | |
| Q3 2016 | -18.8% | -18.0% | -2.1% | |
| Q2 2016 | +10.0% | +12.6% | -3.6% | |
| Q1 2016 | +6.4% | — | — | |
| Q4 2015 | +9.1% | — | — | |
| Q3 2015 | -4.4% | — | — | |
| Q2 2015 | -14.0% | — | — | |
| Q1 2015 | -15.4% | — | — | |
| Q4 2014 | +4.0% | — | — | |
| Q3 2014 | +27.1% | — | — | |
| Q2 2014 | +9.7% | — | — | |
| Q1 2014 | -3.3% | — | — | |
| Q2 2013 | -3.0% | — | — | |
| Q4 2013 | +24.9% | — | — | |
| Q3 2013 | +4.2% | — | — | |
| Q4 2012 | +0.0% | — | — | |
| Q3 2012 | -0.8% | — | — | |
| Q2 2012 | -15.5% | — | — | |
| Q1 2012 | -15.4% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q4 2009 | +0.0% | — | — | |
| Q3 2011 | -6.0% | — | — | |
| Q4 2010 | -7.2% | — | — | |
| Q2 2010 | -7.2% | — | — | |
| Q1 2011 | +0.9% | — | — | |
| Q3 2010 | -6.3% | — | — | |
| Q1 2010 | -5.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro